المصدر: Murphy BR, Prce GA, Colls PL, Van Wyke Coelgh K, Olmsted RA, Sprgs MK, Parrott RH, K HW, Brandt CD, Chanock RM. Current approaches to the development of vacces effecte agast parafluenza and respatory syncytl vuses. Vus Res. 1988 Aug;11(1):1-15. do 10.1016/0168-1702(88)90063-9.
Nolan SM, Skdopoulos MH, Bradley K, K OS, Br S, Amaro-Carambot E, Surman SR, Dav S, St Clae M, Elks R, Colls PL, Murphy BR, Schaap-Nutt A. Recombant human parafluenza vus type 2 vacce candates contag a 3' genom promoter mutatn and L polymerase mutatns are attenuated and protecte non-human prates. Vacce. 2007 Aug 21;25(34):6409-22. do 10.1016/j.vacce.2007.06.028. Epub 2007 Jul 3.
A Phase I Study of the Safety and Immunogenicity of the Recombinant Live-Attenuated Human Parainfluenza Type 2 Virus Vaccine, rHPIV2 15C/948L/Δ1724 Lot PIV2#109C, Delivered as Nose Drops to Adults 18 to 49 Years of Age, HPIV2-Seropositive Children 15 to 59 Months of Age, and HPIV2-Seronegative Infants and Children 6 to 59 Months of Age

الوصول الحر: https://clinicaltrials.gov/ct2/show/NCT01139437Test

المصدر: Karron RA, Belshe RB, Wrht PF, Thumar B, Burns B, Newman F, Cannon JC, Thompson J, TsaT, Paschal M, Wu SL, Mcho Y, Hackell J, Murphy BR, Tatem JM. A le human parafluenza type 3 vus vacce attenuated and munogen young fants. Pedtr fect D J. 2003 May;22(5):394-405. do 10.1097/01.f.0000066244.31769.83.
Durb AP, Karron RA. Progress the development of respatory syncytl vus and parafluenza vus vacces. Cl fect D. 2003 Dec 15;37(12):1668-77. do 10.1086/379775. Epub 2003 Nov 20.
Phase 1 Study to Determine the Safety, Infectivity, Immunogenicity and Tolerability of 2 Doses of Live Attenuated Recombinant Cold-passaged (cp) 45 Human Parainfluenza Type 3 Virus Vaccine, rHPIV3cp45, Lot PIV3#102A, Delivered as Nose Drops to HPIV3-Seronegative Infants and Children 6 to 36 Months of Age, at a 6 Month Interval

الوصول الحر: https://clinicaltrials.gov/ct2/show/NCT01254175Test